Search Results | Blood | American Society of Hematology

1-20 of 367

2 3 4 5

Sort by

Sort Order Select

Journal Articles

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis

Bethany Samuelson Bannow, Deepti M. Warad, Curtis G. Jones, Shannon M. Pechauer, Brian R. Curtis, Daniel W. Bougie, Ruchika Sharma, Diane E. Grill, Mary W. Redman, Parisa R. Khalighi, Rachel R. Leger, Rajiv K. Pruthi, Dong Chen, Daniel E. Sabath, Richard H. Aster, David A. Garcia, Anand Padmanabhan

Blood (2021) 137 (8): 1082–1089.

DOI: https://doi.org/10.1182/blood.2020008195

Published: 2021

Includes: Supplemental data

Journal Articles

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Adam J Olszewski, MD, Thomas A Ollila, MD, John L. Reagan, MD

Blood (2019) 134 (Supplement_1): 2824.

DOI: https://doi.org/10.1182/blood-2019-121841

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

DOI: https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Ian Gould, PhD, Jan Bassali, PharmD, Jyotsna Mehta, Jatin Shah, MD, Dee Dee Mladsi, BA

Blood (2019) 134 (Supplement_1): 5824.

DOI: https://doi.org/10.1182/blood-2019-125997

Published: 2019

Journal Articles

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Betul Oran, MDMS, Kwang Woo Ahn, PhD, Caitrin Fretham, Mithun Vinod Shah, MD PhD, Ryotaro Nakamura, MD, Bart L. Scott, MD, Ronald Sobecks, MD, Uday Popat, MD, Wael Saber, MD MS

Blood (2019) 134 (Supplement_1): 253.

DOI: https://doi.org/10.1182/blood-2019-121970

Published: 2019

Journal Articles

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Marc Botteman, MS, MA, Ruchit Shah, PhD, Linlin Luo, MSc, Zhenming Shun, PhD, Saurabh Ray, PhD

Blood (2019) 134 (Supplement_1): 382.

DOI: https://doi.org/10.1182/blood-2019-123554

Published: 2019

Journal Articles

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

Alexandre Sostelly, M.Eng., PhD, Antoine Soubret, Christoph Bucher, MD, Simon Buatois, Jean-Eric Charoin, Gregor Jordan, Barbara Klughammer, PhD, Andreas Dieckmann, Taku Fukuzawa, PhD, Keisuke Gotanda, Kenji Shinomiya, Sung-Soo Yoon, MD PhD, Jens P. Panse, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD, Zsolt Nagy, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 1227.

DOI: https://doi.org/10.1182/blood-2019-126911

Published: 2019

Journal Articles

A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies

Srikumar Sahasranaman, PhD, Oleg Demin, Jr., Dmitry Shchelokov, Veronika Musatova, Nageshwar Budha, PhD, Ying Ou, PhD

Blood (2019) 134 (Supplement_1): 1289.

DOI: https://doi.org/10.1182/blood-2019-129133

Published: 2019

Journal Articles

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Ha Anh Pham, MSc, Sandra Milev, Shujun Li, Denise Zou, Yannan Hu, PhD, Bart Heeg, PhD, Timothy J Bell, MHA

Blood (2019) 134 (Supplement_1): 5852.

DOI: https://doi.org/10.1182/blood-2019-122709

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 5085.

DOI: https://doi.org/10.1182/blood-2019-123811

Published: 2019

Journal Articles

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Cynthia Z. Qi, MBA, Xinglei Chai, PhD, Eric Q Wu

Blood (2019) 134 (Supplement_1): 4723.

DOI: https://doi.org/10.1182/blood-2019-129215

Published: 2019

Journal Articles

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Vladimir Hanes, MD, Jean Pan, Daniel T. Mytych, PhD, David Chien, MD, Vincent Chow

Blood (2019) 134 (Supplement_1): 3520.

DOI: https://doi.org/10.1182/blood-2019-128621

Published: 2019

Journal Articles

Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis

Ang Li, MD, Josh J Carlson, PhD, Nicole M. Kuderer, Jordan K Schaefer, MD, Shan Li, PharmD, David A. Garcia, MD, Alok A Khorana, MD, Marc Carrier, MD, Gary H. Lyman, MD MPH

Blood (2019) 134 (Supplement_1): 4669.

DOI: https://doi.org/10.1182/blood-2019-127917

Published: 2019

Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek

Blood (2019) 134 (Supplement_1): 4741.

DOI: https://doi.org/10.1182/blood-2019-123706

Published: 2019

Journal Articles

Primary Prophylaxis with Pegfilgrastim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Nation-Wide, Propensity Score Based Analysis

Kensuke Matsuda, MD, Taisuke Jo, Masashi Miyauchi, MD PhD, Kazuhiro Toyama, MD PhD, Kumi Nakazaki, Hideo Yasunaga, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 1605.

DOI: https://doi.org/10.1182/blood-2019-123611

Published: 2019

Journal Articles

Quantitative Modeling of Azacitidine Resistance in Patients with Myelodysplastic Syndrome Identifies Distinct Phenotypes of Disease Progression: Evidence for the Presence of a Disease Versus Native Clone Effect

Roman M Shapiro, MD, Adam R Stinchcombe, PhD

Blood (2019) 134 (Supplement_1): 1723.

DOI: https://doi.org/10.1182/blood-2019-130332

Published: 2019

Journal Articles

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

Carmen Fava, Paola Berchialla, PhD, Jessica Petiti, PhD, Maria Teresa Bochicchio, Barbara Izzo, PhD, Emilia Giugliano, Emanuela Ottaviani, Santa Errichiello, PhD, Giovanna Rege Cambrin, MD PhD, Claudia Venturi, Luigiana Luciano, Filomena Daraio, Daniele Calistri, Alessandro Martino, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Fabrizio Pane, MD, Daniela Cilloni, MD PhD, Enrico Marco Gottardi

Blood (2019) 134 (Supplement_1): 2092.

DOI: https://doi.org/10.1182/blood-2019-125614

Published: 2019

Journal Articles

Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)

Alix E. Seif, MD, Yimei Li, PhD, Viviane C. Cahen, Yuan-Shung V. Huang, MS, Matt Hall, PhD, E. Anders Kolb, MD, Brian T. Fisher, DO, MSCE, Richard Aplenc, MD PhD, Kelly D Getz

Blood (2019) 134 (Supplement_1): 3496.

DOI: https://doi.org/10.1182/blood-2019-122887

Published: 2019

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

DOI: https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Xinglei Chai, PhD, Cynthia Z. Qi, MBA, Eric Q Wu

Blood (2019) 134 (Supplement_1): 3419.

DOI: https://doi.org/10.1182/blood-2019-129070

Published: 2019

2 3 4 5

NARROW

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis

Bendamustine-Rituximab Does Not Improve Survival over Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Primary Prophylaxis with Pegfilgrastim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Nation-Wide, Propensity Score Based Analysis

Quantitative Modeling of Azacitidine Resistance in Patients with Myelodysplastic Syndrome Identifies Distinct Phenotypes of Disease Progression: Evidence for the Presence of a Disease Versus Native Clone Effect

A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia

Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only